论文部分内容阅读
目的:探讨GH-IGF与肝脏疾病的相互关系、生长激素在肝脏疾病中应用以及rhGH在重型肝炎中的治疗价值。方法:采用文献报道的生长激素在肝脏疾病中应用的临床方法并选用队列研究设计方法研究了2001年1月~2004年1月住院治疗的重型病毒性肝炎患者106例,在实际临床资料中采用ELISA法测定血清GH、IGF-1、IGFBP-3、胰岛素:晨起6~7点抽取外周静脉血3ml,4℃低温离心分离血清,-20℃储存。结果:通过对治疗组和对照组临床症状改善结果的比较、治疗组患者的不良反应、治疗组和对照组生化指标的比较、治疗组和对照组6月内生存率比较以及比较重型肝炎患者血清生长激素—胰岛素生长因子轴变化,初步发现,慢性重型肝炎患者经rhGH治疗2周后,IGF-1、IGFBP-2增加者,其生存时间长;相反,IGF-1、IGFBP-3无变化或降低者,2周内几乎100%死亡。结论:人生长激素联合乳果糖是防止重型肝炎患者病情恶化的有效方法,能有效的防止其并发症的发生发展,提高患者的生存率。RhGH可以改善慢性重型肝炎患者异常的GH-IGFs轴,延长其存活时间,具有重要的治疗价值。
Objective: To investigate the relationship between GH-IGF and liver diseases, the application of growth hormone in liver diseases and the therapeutic value of rhGH in severe hepatitis. Methods: The reported clinical application of growth hormone in liver diseases and selected cohort study design method to study 106 patients with severe viral hepatitis who were hospitalized from January 2001 to January 2004, which were used in the actual clinical data Serum GH, IGF-1, IGFBP-3 and insulin were measured by ELISA. Peripheral venous blood was extracted from 6 to 7 morning and serum was extracted by centrifugation at 4 ℃ and stored at -20 ℃. Results: By comparing the clinical symptoms of the treatment group and the control group, the adverse reactions of the treatment group, the biochemical indexes of the treatment group and the control group, the comparison of the 6-month survival rate between the treatment group and the control group and the comparison of the serum levels of the severe hepatitis patients Growth hormone - insulin growth factor axis changes, preliminary found that patients with chronic severe hepatitis after rhGH treatment for 2 weeks, IGF-1, IGFBP-2 increased their survival time; the contrary, IGF-1, IGFBP-3 no change or Reduced, almost 100% died within 2 weeks. Conclusion: Human growth hormone combined with lactulose is an effective way to prevent the progression of severe hepatitis patients. It can effectively prevent the occurrence and development of complications and improve the survival rate of patients. RhGH can improve the abnormal GH-IGFs axis in patients with chronic severe hepatitis and prolong its survival time, which has important therapeutic value.